VEGF-RII Influences the Prognosis of Pancreatic Cancer

ObjectiveTo evaluate whether the vascular endothelial growth factor (VEGF) pathway can be used as a target for effective treatment of pancreatic cancer. Summary Background DataVEGF and its receptors (VEGF-RI and -RII) are the predominant regulators of tumor neoangiogenesis, a key element for tumor growth and progression. However, VEGF receptor expression has been thought to be limited to endothelial cells, limiting the possibility of targeting it for therapy of pancreatic cancer. MethodsProtein localization and mRNA were studied in pancreatic cancer specimens, normal pancreas, human pancreatic cancer cell lines, and an endothelial cell line. Cell proliferation was determined by [3H] thymidine uptake. Both VEGF receptors were genetically eliminated by antisense technology. The same approach was used in a murine model of pancreatic cancer in a therapeutic approach. ResultsVEGF-RI mRNA and VEGF-RII mRNA were expressed in 17 and 15 of 24 pancreatic cancer samples, respectively. VEGF receptors were found not only in blood vessels but also in pancreatic cancer cells. VEGF-RII expression correlated with poor tumor differentiation and was associated with poorer survival, while VEGF-RI expression did not correlate. VEGF treatment led to extensive growth stimulation in six of seven pancreatic cancer cell lines, which was completely inhibited by antisense treatment against VEGF-RII. Liposome-mediated gene transfer in nude mice with pancreatic tumors markedly reduced local tumor growth and decreased metastatic tumor spread. ConclusionsThe VEGF/VEGF-RII pathway regulates angiogenesis and local tumor growth and spread in pancreatic cancer. Genetic targeting of VEGF-RII blocks local growth and metastatic spread of pancreatic cancer cells in vivo and therefore offers a potential new therapeutic option for patients with this disease.

[1]  D. Hanahan,et al.  Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. , 1995, Molecular endocrinology.

[2]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[3]  J. Folkman,et al.  Tumoral vascularity as a prognostic factor in cancer. , 1996, Important advances in oncology.

[4]  M. Tempero,et al.  AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. , 1999, Gastroenterology.

[5]  R. Masood,et al.  Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[7]  H. Hameister,et al.  Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells , 1999, Oncogene.

[8]  H. Reber,et al.  Animal models of exocrine pancreatic cancer , 2000, International Journal of Colorectal Disease.

[9]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[10]  T. Grogan,et al.  Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.

[11]  A. Yunis,et al.  Human pancreatic carcinoma (mia paca‐2) in continuous culture: Sensitivity to asparaginase , 1977, International journal of cancer.

[12]  M. Welsh,et al.  Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro , 1997, Molecular and Cellular Endocrinology.

[13]  M. Rao,et al.  Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. , 1982, The American journal of pathology.

[14]  D. Mukhopadhyay,et al.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.

[15]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[16]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[17]  F. Guadagni,et al.  A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Claesson‐Welsh,et al.  Expression of protein tyrosine kinases in islet cells: possible role of the Flk-1 receptor for beta-cell maturation from duct cells. , 1994, Growth factors.

[19]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  D. Gospodarowicz,et al.  Characterization of the receptors for vascular endothelial growth factor. , 1990, The Journal of biological chemistry.

[21]  S. Soker,et al.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.

[22]  B. Wiedenmann,et al.  De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. , 2000, Gastroenterology.

[23]  P. Gleizes,et al.  Cell Release of Bioactive Fibroblast Growth Factor 2 by Exon 6-encoded Sequence of Vascular Endothelial Growth Factor* , 1997, The Journal of Biological Chemistry.

[24]  I. Rooman,et al.  Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[25]  Z. Shao,et al.  Genistein exerts multiple suppressive effects on human breast carcinoma cells. , 1998, Cancer research.

[26]  R. Halaban,et al.  Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. , 1993, Biochemical and biophysical research communications.

[27]  J. Cameron,et al.  Improved hospital morbidity, mortality, and survival after the Whipple procedure. , 1987, Annals of surgery.

[28]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[29]  A. Abioye,et al.  Pancreatic carcinoma. , 2020, Journal of the National Medical Association.

[30]  A. Al-Mehdi,et al.  Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis , 2000, Nature Medicine.

[31]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[32]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[33]  C. Peschle,et al.  KDR receptor: a key marker defining hematopoietic stem cells. , 1999, Science.

[34]  R. Dickson,et al.  Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. , 2001, The American journal of pathology.

[35]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[36]  C. Goodman,et al.  Neuropilin-2, a Novel Member of the Neuropilin Family, Is a High Affinity Receptor for the Semaphorins Sema E and Sema IV but Not Sema III , 1997, Neuron.

[37]  D. Hanahan,et al.  Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. , 1997, Cancer research.

[38]  Brygida Berse,et al.  Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.

[39]  J. Pouysségur,et al.  Angiogenesis: how a tumor adapts to hypoxia. , 1999, Biochemical and biophysical research communications.

[40]  P. Wingo,et al.  Cancer statistics by race and ethnicity , 1998, CA: a cancer journal for clinicians.

[41]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[42]  H. Moukadiri,et al.  Characterization of the receptor to vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. , 1990, The Journal of biological chemistry.

[43]  H. Friess,et al.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  D. Gospodarowicz,et al.  Pituitary follicular cells secrete both vascular endothelial growth factor and follistatin. , 1989, Biochemical and biophysical research communications.

[45]  M. Lieber,et al.  Establishment of a continuous tumor‐cell line (PANC‐1) from a human carcinoma of the exocrine pancreas , 1975, International journal of cancer.

[46]  H. Friess,et al.  Expression and in‐situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer , 1995, International journal of cancer.

[47]  G. Palade,et al.  Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.